2022
DOI: 10.1530/endoabs.81.p159
|View full text |Cite
|
Sign up to set email alerts
|

What is the relevance of he systematic use of gadolinium (Gd) during the MRI follow-up of non-functioning pituitary adenomas (NFPAs)?

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles